



STW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on January 18, 2006.

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE  
STATEMENT

Examining Group 1637  
Patent Application  
Docket No. INN-113TD2  
Serial No. 10/633,771

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Bradley L. Sisson  
Art Unit : 1637  
Applicants : Eric Vivier, Frederic Vely  
Serial No. : 10/633,771  
Filed : August 4, 2003  
Conf. No. : 6493  
For : Means of Documenting Repertoires of NKR Immunoreceptors and/or of  
Activatory of Non-Inhibitory Immunoreceptor Counterparts of NKR  
Immunoreceptors

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98


Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/633,771
				Filing Date	August 4, 2003
				First Named Inventor	Eric Vivier
				Art Unit	1637
				Examiner Name	Bradley L. Sisson
Sheet	1	of	8	Attorney Docket Number	INN-113TD2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-5,976,819	11-02-1999	Finkel et al.	ALL
	U2	US-6,307,021	10-23-2001	Bandman et al.	ALL
	U3	US-2005-0191695 A1	09-01-2005	Vivier et al.	ALL
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/633,771	
			Filing Date	August 4, 2003	
			First Named Inventor	Eric Vivier	
			Group Art Unit	1637	
			Examiner Name	Bradley L. Sisson	
Sheet	2	of	8	Attorney Docket Number	INN-113TD2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	R1	ADAMKIEWICZ, T.V. <i>et al.</i> Natural killed lectin-like receptors have divergent carboxy-termini, distinct from C-type lectins. <i>Immunogenetics</i> 39:218 (1994).		
	R2	ALBI, N. <i>et al.</i> Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "Three-Loci" HLA-incompatible bone marrow transplantation. <i>Blood</i> 87:3993-4000 (1998).		
	R3	BAKER, E.A., D'Andrea, J.H., Phillips, G.R. and Lanier, L.L. Natural killer cell receptor for HLA-B allotypes, NKB1: Map position 19q13.4. <i>Chromosome Res.</i> 3, 511 (1995).		
	R4	BECKMAN COULTER FLOW CYTOMETRY CLONE DETAIL: 276 for GL183. World Wide Web Beckman.com/products/instrument/flowcytometry/ecatalog/clonedetail.asp?cloneid=276		
	R5	BIASSONI, R., Pessino, A., Malaspina, A., Cantoni, C., Bottino, C., Sivori, S., Moretta, L. and Moretta, A. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. <i>Eur. J. Immunol.</i> 27 (12), 3095-3099 (1997).		
	R6	BIASSONI, R., Cantoni, C., Falco, M., Verdiani, S., Bottino, C., Vitale, M., Conte, R., Poggi, A., Moretta, A. and Moretta, L. The human leukocyte antigen (HLA)-C-specific 'activatory' or 'inhibitory' natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. <i>J. Exp. Med.</i> 183 (2), 645-650 (1996).		
	R7	BOTTINO, C. <i>et al.</i> A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell function and proliferation. <i>Eur. J. Immunol.</i> 26:1816-1824 (1996).		
	R8	CAMBIAGGI, A. <i>et al.</i> Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor (CD158b). <i>Proc. Natl. Acad. Sci.</i> 94:8088-8092 (1997).		
	R9	CANTONI, C. <i>et al.</i> Molecular structures of HLA-specific human NK cell receptors. <i>Chem. Immunol.</i> 64:88-1003 (1996).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/633,771	
			Filing Date	August 4, 2003	
			First Named Inventor	Eric Vivier	
			Group Art Unit	1637	
			Examiner Name	Bradley L. Sisson	
Sheet	3	of	8	Attorney Docket Number	INN-113TD2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R10	COLONNA, M. and Samaridis, J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. <i>Science</i> 268 (5209), 405-408 (1995).	
	R11	D'ANDREA, A., Chang, C., Franz-Bacon, K., McClanahan, T., Phillips, J.H. and Lanier, L.L. Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. <i>J. Immunol.</i> 155 (5), 2306-2310 (1995).	
	R12	DOHRING, C., Samaridis, J. and Colonna, M. Alternatively spliced forms of human killer inhibitory receptors. <i>Immunogenetics</i> 44 (3), 227-230 (1996).	
	R13	HEUNER, K., Hacker, J. and Brand, B.C. The alternative sigma factor sigma28 of <i>Legionella pneumophila</i> restores flagellation and motility to an <i>Escherichia coli</i> fliA mutant. <i>J. Bacteriol.</i> 179 (1), 17-23 (1997).	
	R14	HIBY, S.E. <i>et al.</i> Human uterine Nk cells have a similar repertoire of killer inhibitory and activatory receptors to those found in blood, as demonstrated by RT-PCR and sequencing. <i>Molecular Immunity</i> 34(5):419-430 (1997).	
	R15	HOUCHINS, J.P., Yabe, T., McSherry, C. and Bach, F.H. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. <i>J. Exp. Med.</i> 173 (4), 1017-1020 (1991).	
	R16	LONG, E.O. <i>et al.</i> Killer cell inhibitory receptors: diversity, specificity, and function. <i>Immunol Rev.</i> 155:135-144 (1997).	
	R17	MATTHEWS, J.A. and L.J. Kricka. Analytical strategies for the use of DNA probes. <i>Anal. Biochem.</i> 169:1-25 (1998).	
	R18	MINGARI, M.C. <i>et al.</i> Interleukin-15-induced maturation of human natural killer cells from early thymic precursors : selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. <i>Eur. J. Immunol.</i> 27:1374-1380 (1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/633,771
				Filing Date	August 4, 2003
				First Named Inventor	Eric Vivier
				Group Art Unit	1637
				Examiner Name	Bradley L. Sisson
Sheet	4	of	8	Attorney Docket Number	INN-113TD2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R19	PENDE, D., Biassoni, R., Cantoni, C., Verdiani, S., Falco, M., di Donato, C., Accame, L., Bottino, C., Moretta, A. and Moretta, L. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimmer. <i>J. Exp. Med.</i> 184 (2), 505-518 (1996).	
	R20	RENARD V. <i>et al.</i> Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes. <i>Immunol Rev.</i> 155:205-221 (1997).	
	R21	SALTER, R.D. <i>et al.</i> Domain organization and sequence relationship of killer cell inhibitory receptors. <i>Immunol. Rev.</i> 155:175-182 (1997).	
	R22	SELVAKUMAR, A., Steffens, U. and Dupont, B. Polymorphism and domain variability of human killer cell inhibitory receptors. <i>Immunol. Rev.</i> 155, 183-196 (1997).	
	R23	SELVAKUMAR, A., Steffens, U. and Dupont, B. NK cell receptor gene of the KIR family with two IG domains but highest homology to KIR receptors with three IG domains. <i>Tissue Antigens</i> 48 (4 Pt), 285-294 (1996.)	
	R24	VELY, F. <i>et al.</i> Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements. <i>J. Immunol.</i> 166:2487-2494 (2001).	
	R25	WAGTMANN, N., Biassoni, R., Cantoni, C., Verdiani, S., Malnati, M.S., Vitale, M., Bottino, C., Moretta, L., Moretta, A. and Long, E.O. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. <i>Immunity</i> 2 (5), 439-449 (1995).	
	R26	WAGTMANN, N., Rajagopalan, S., Winter, C.C., Peruzzi, M. and Long, E.O. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. <i>Immunity</i> 3 (6), 801-809 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/633,771	
			Filing Date	August 4, 2003	
			First Named Inventor	Eric Vivier	
			Group Art Unit	1637	
			Examiner Name	Bradley L. Sisson	
Sheet	5	of	8	Attorney Docket Number	INN-113TD2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R27	YABE, T. et al. A multigene family on human chromosome 12 encodes natural killer-cell lectins. Immunogenetics 37:455-460 (1993).	
	R28	NCBI DATABASE Genbank Accession No. U24076, March 23, 2005.	
	R29	NCBI DATABASE Genbank Accession No. L41267, March 23, 2005.	
	R30	NCBI DATABASE Genbank Accession No. U24078, March 23, 2005.	
	R31	NCBI DATABASE Genbank Accession No. X98858, March 23, 2005.	
	R32	NCBI DATABASE Genbank Accession No. X98892, March 23, 2005.	
	R33	NCBI DATABASE Genbank Accession No. L76670, March 23, 2005.	
	R34	NCBI DATABASE Genbank Accession No. L76672, March 23, 2005.	
	R35	NCBI DATABASE Genbank Accession No. U24075, March 23, 2005.	
	R36	NCBI DATABASE Genbank Accession No. L76669, March 23, 2005.	
	R37	NCBI DATABASE Genbank Accession No. LL76663, March 23, 2005.	
	R38	NCBI DATABASE Genbank Accession No. L7U24074, March 23, 2005.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/633,771
				Filing Date	August 4, 2003
				First Named Inventor	Eric Vivier
				Group Art Unit	1637
				Examiner Name	Bradley L. Sisson
Sheet	6	of	8	Attorney Docket Number	INN-113TD2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R39	NCBI DATABASE Genbank Accession No. L41268, March 23, 2005.	
	R40	NCBI DATABASE Genbank Accession No. U73395, March 23, 2005.	
	R41	NCBI DATABASE Genbank Accession No. L76662, March 23, 2005.	
	R42	NCBI DATABASE Genbank Accession No. L76664, March 23, 2005.	
	R43	NCBI DATABASE Genbank Accession No. U24079, March 23, 2005.	
	R44	NCBI DATABASE Genbank Accession No. L41347, March 23, 2005.	
	R45	NCBI DATABASE Genbank Accession No. X89893, March 23, 2005.	
	R46	NCBI DATABASE Genbank Accession No. U24077, March 23, 2005.	
	R47	NCBI DATABASE Genbank Accession No. L76671, March 23, 2005.	
	R48	NCBI DATABASE Genbank Accession No. L76667, March 23, 2005.	
	R49	NCBI DATABASE Genbank Accession No. X94262, March 23, 2005.	
	R50	NCBI DATABASE Genbank Accession No. L41269, March 23, 2005.	
	R51	NCBI DATABASE Genbank Accession No. U31416, March 23, 2005.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/633,771	
			Filing Date	August 4, 2003	
			First Named Inventor	Eric Vivier	
			Group Art Unit	1637	
			Examiner Name	Bradley L. Sisson	
Sheet	7	of	8	Attorney Docket Number	INN-113TD2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R52	NCBI DATABASE Genbank Accession No. U33328, March 23, 2005.	
	R53	NCBI DATABASE Genbank Accession No. U71199, March 23, 2005.	
	R54	NCBI DATABASE Genbank Accession No. U73394, March 23, 2005.	
	R55	NCBI DATABASE Genbank Accession No. X94373, March 23, 2005.	
	R56	NCBI DATABASE Genbank Accession No. U30274, March 23, 2005.	
	R57	NCBI DATABASE Genbank Accession No. U30273, March 23, 2005.	
	R58	NCBI DATABASE Genbank Accession No. L76661, March 23, 2005.	
	R59	NCBI DATABASE Genbank Accession No. U73396, March 23, 2005.	
	R60	NCBI DATABASE Genbank Accession No. L41270, March 23, 2005.	
	R61	NCBI DATABASE Genbank Accession No. X94374, March 23, 2005.	
	R62	NCBI DATABASE Genbank Accession No. X93595, March 23, 2005.	
	R63	NCBI DATABASE Genbank Accession No. X93596, March 23, 2005.	
	R64	NCBI DATABASE Genbank Accession No. L76666, March 23, 2005.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/633,771
				Filing Date	August 4, 2003
				First Named Inventor	Eric Vivier
				Group Art Unit	1637
				Examiner Name	Bradley L. Sisson
Sheet	8	of	8	Attorney Docket Number	INN-113TD2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R65	NCBI DATABASE Genbank Accession No. L76665, March 23, 2005.	
	R66	NCBI DATABASE Genbank Accession No. U30272, March 23, 2005.	
	R67	NCBI DATABASE Genbank Accession No. X54867, March 23, 2005.	
	R68	NCBI DATABASE Genbank Accession No. X54868, March 23, 2005.	
	R69	NCBI DATABASE Genbank Accession No. X54869, March 23, 2005.	
	R70	NCBI DATABASE Genbank Accession No. X54870, March 23, 2005.	
	R71	GeneCard database printout for GenBank Accession No. U24076, pp. 1-7 (for Human Gene Nomenclature database symbol KIR2DL1 (killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail,1)).	
	R72		
	R73		
	R74		
	R75		
	R76		
	R77		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2